Xintela broadens and extends patent protection for chondrocyte products and chondrocyte markers

The patent application relates to a further development of Xintela's marker technology and quality test XACT and protects chondrocyte preparations of high-quality and purity as well as methods to isolate chondrocytes using a combination of the cell markers integrin a10b1 and integrin a11b1. Chondrocytes, quality assured with Xintela's quality assay XACT have both regulatory and functional advantages in cell therapy of cartilage damage. The European Patent Office (EPO), which has examined the international patent application, has concluded that it is both novel and inventive.

"This patent application demonstrates our proactive approach to create strong and long-term protection of our portfolio technologies and importantly, it also strengthens our position in collaboration discussions with companies that develop chondrocyte products. The positive examination report from the EPO is very promising, not least considering that the national patent authorities in many other territories tends to follow the opinion of the EPO in their assessments", says Xintela's CEO Evy Lundgren-Åkerlund.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: [email protected] 
Medicon Village
223 81 Lund
www.xintela.se 

The following documents can be retrieved from beQuoted
Xintela Pressrelease 2019-01-08.pdf

About Xintela
Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company's oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.